Van Baelen Anthony, Mottet Nicolas, Spahn Martin, Briganti Alberto, Gontero Paolo, Joniau Steven
Department of Urology, University Hospitals Leuven, 3000 Leuven, Belgium.
Adv Urol. 2012;2012:983058. doi: 10.1155/2012/983058. Epub 2011 Oct 9.
Lymph node metastases associated with prostate cancer (PCa) has been shown to be a poor prognostic factor. The role of pelvic lymph node dissection (PLND) itself in relation to survival remains unclear, however. A Medline search was conducted to address this issue. The following conclusions were drawn. Only recently, improved survival due to completion of radical prostatectomy (RP) (compared to abandoning RP) in known or presumed lymph-node-positive patients has been shown. Lymph node sampling can only be considered representative if an adequate number of nodes is removed. While several authors have suggested that a therapeutic benefit in patients undergoing RP is not provided by PLND, the reliability of these studies is uncertain. Contrary to this, several studies have indicated the possibility of long-term survival even in the presence of limited lymph node metastases. The role and timing of initiation of adjuvant androgen deprivation therapy (ADT) in patients who have node-positive disease after RP is controversial. Recent studies suggest that delaying ADT may not adversely impact survival.
与前列腺癌(PCa)相关的淋巴结转移已被证明是一个不良预后因素。然而,盆腔淋巴结清扫术(PLND)本身对生存的作用仍不清楚。为解决这一问题进行了医学文献数据库检索。得出了以下结论。直到最近,才显示出在已知或推测为淋巴结阳性的患者中,完成根治性前列腺切除术(RP)(与放弃RP相比)可提高生存率。只有切除足够数量的淋巴结,淋巴结取样才能被认为具有代表性。虽然几位作者认为PLND对接受RP治疗的患者没有治疗益处,但这些研究的可靠性尚不确定。与此相反,一些研究表明,即使存在有限的淋巴结转移,也有长期生存的可能性。RP后淋巴结阳性疾病患者辅助雄激素剥夺治疗(ADT)开始的作用和时机存在争议。最近的研究表明,推迟ADT可能不会对生存产生不利影响。